What is the 13F Pro Quality Score for FLGT?

13F Pro ranks Fulgent Genetics, Inc. (FLGT) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View FLGT's current score at https://13fpro.ai/research/FLGT (free sign-up required for the full ranking).

Which hedge funds own the most FLGT stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of FLGT include BlackRock,, RTW INVESTMENTS,, VANGUARD CAPITAL MANAGEMENT. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/FLGT as soon as new 13F filings post.

Where does 13F Pro source FLGT data?

All Fulgent Genetics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Fulgent Genetics, Inc. files with the SEC under CIK 1674930. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is FLGT in?

Fulgent Genetics, Inc. (FLGT) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is FLGT research updated on 13F Pro?

FLGT's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Fulgent Genetics, Inc.(FLGT)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1674930 FLGT stock profile & AI dashboard →

13F Pro Quality Score

27.2/100

Rank #2,472 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

49.6/100

Profitability

15.8/100

Balance Sheet

23.9/100

Earnings Quality

30.0/100

Free Cash Flow

17.2/100

Institutional Flow

23.8/100

Revenue Scale

30.1/100

Dilution Risk

14.7/100

FLGT Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Fulgent Genetics, Inc. (FLGT), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores FLGT at 27.2/100 on a 32-signal composite quality model, placing it at rank #2,472 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include profitability (15.8) and free cash flow (17.2), which score below median versus the broader universe. Shareholder dilution risk is elevated at 14.7/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Fulgent Genetics, Inc. reports quarterly revenue of $71.1M, net income of $-24.8M, free cash flow of $1.9M. Top institutional holders of FLGT by reported 13-F value include BlackRock,, RTW INVESTMENTS,, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. FLGT trades on the Nasdaq exchange and files with the SEC under CIK 1674930. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate FLGT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Fulgent Genetics, Inc. directly from SEC EDGAR. Fulgent Genetics, Inc.'s 13F Pro composite quality score has ranged between 8 and 86 since 2021, currently 27.2 — a declining long-term trajectory across 56 quarterly and live scoring snapshots.

✦

Fun facts about Fulgent Genetics, Inc.

Quirks, history, and lore behind FLGT — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. healthcare company · small-cap · listed on Nasdaq · headquartered in Southern California.
2
The Numbers
Revenue surged to over $1 billion at its pandemic peak before retreating sharply — a classic tale of boom-and-bust testing demand.
3
The History
Founded in 2011, it spent its early years as a quiet genomic testing services company before COVID-19 turned it into a household name almost overnight.
4
The Secret
Its core technology is a proprietary multiplex sequencing platform that lets it run many different genetic tests cheaply and at scale — the same engine that powered its COVID PCR testing blitz.
5
The Lore
At the height of the pandemic it was processing millions of COVID tests for schools, employers, and government agencies — not bad for a company most investors had never heard of before 2020.
6
The Giveaway
A genomics and precision medicine company whose ticker rhymes with 'flight' — this Temple City, California lab quietly sequenced its way from obscurity to billion-dollar revenues and back again.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$71.1M

Net Income

Q1 2026

$-24.8M

Free Cash Flow

Q1 2026

$1.9M

ROIC

Q1 2026

-3.3%

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+13.8% YoY

$322.7MFY 2025

FY22 $619.0MFY23 $289.2MFY24 $283.5MFY25 $322.7M

Net Income

-41.7% YoY

$-60.5MFY 2025

FY22 $143.4MFY23 $-167.8MFY24 $-42.7MFY25 $-60.5M

Operating Income

-23.2% YoY

$-91.1MFY 2025

FY22 $178.5MFY23 $-195.5MFY24 $-73.9MFY25 $-91.1M

Total Assets

-0.5% YoY

$1.21BFY 2025

FY22 $1.39BFY23 $1.24BFY24 $1.22BFY25 $1.21B

Op. Cash Flow

-582.6% YoY

$-101.6MFY 2025

FY22 $253.5MFY23 $27.0MFY24 $21.1MFY25 $-101.6M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2019
Revenue	$322.7M +13.8%	$283.5M -2.0%	$289.2M -53.3%	$619.0M -37.6%	$992.6M +2951.5%	$32.5M
Net Income	$-60.5M -41.7%	$-42.7M +74.6%	$-167.8M -217.0%	$143.4M -71.7%	$507.4M +123546.2%	$-411.0K
Operating Income	$-91.1M -23.2%	$-73.9M +62.2%	$-195.5M -209.5%	$178.5M -73.6%	$676.0M +158032.9%	$-428.0K
Total Assets	$1.21B -0.5%	$1.22B -1.2%	$1.24B -10.9%	$1.39B +8.4%	$1.28B +1340.7%	$88.8M
Operating Cash Flow	$-101.6M -582.6%	$21.1M -22.0%	$27.0M -89.3%	$253.5M -52.9%	$538.6M +9662.1%	$5.5M

AI Insight: FLGT Financial Trends

FLGT shows revenue volatility with persistent operating losses deepening to -$35M in Q1 2026 while equity eroded $83M over two years.

• Revenue fluctuated between $71M-$84M across eight quarters with no clear growth trajectory, ending at $71M in Q1 2026.

• Operating losses persisted throughout the period, worsening from -$19M in Q2 2024 to -$35M in Q1 2026.

• Equity declined from $1,133M in Q2 2024 to $1,050M in Q1 2026, reflecting cumulative losses.

⚠ Operating cash flow turned sharply negative to -$78M in Q4 2025, the worst quarterly performance in the dataset.

⚠ Net losses widened to -$25M in Q1 2026 from -$9M in Q2 2024 despite revenue remaining flat.

AI Insight: FLGT Ratio Trends

Operating losses deepened dramatically with operating margin collapsing from -18.3% in Q3 2025 to -48.7% in Q1 2026.

• Operating margin deteriorated severely from -18.3% in Q3 2025 to -48.7% in Q1 2026.

• Net profit margin plunged from -7.9% in Q3 2025 to -34.9% in Q1 2026.

• ROIC declined from -5.5% in Q3 2025 to -13.2% in Q1 2026.

• ROE weakened from -2.4% in Q3 2025 to -9.5% in Q1 2026.

⚠ Company remains deeply unprofitable across all metrics with no clear path to recovery visible.

⚠ Recent quarterly deterioration suggests operational challenges are intensifying rather than stabilizing.

Get alerted when FLGT's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Fulgent Genetics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of FLGT

BlackRock, Inc.
$44.1M2,774,519 sh
RTW INVESTMENTS, LP
$20.5M1,289,000 sh
VANGUARD CAPITAL MANAGEMENT LLC
$14.0M880,150 sh
DIMENSIONAL FUND ADVISORS LP
$10.7M671,664 sh
Invenomic Capital Management LP
$9.7M610,318 sh
GEODE CAPITAL MANAGEMENT, LLC
$9.3M584,207 sh
AMERIPRISE FINANCIAL INC
$9.0M563,375 sh
STATE STREET CORP
$8.4M529,399 sh
D. E. Shaw & Co., Inc.
$7.7M486,770 sh
MILLENNIUM MANAGEMENT LLC
$6.4M401,819 sh

Fund	Value	Shares
BlackRock, Inc.	$44.1M	2,774,519
RTW INVESTMENTS, LP	$20.5M	1,289,000
VANGUARD CAPITAL MANAGEMENT LLC	$14.0M	880,150
DIMENSIONAL FUND ADVISORS LP	$10.7M	671,664
Invenomic Capital Management LP	$9.7M	610,318
GEODE CAPITAL MANAGEMENT, LLC	$9.3M	584,207
AMERIPRISE FINANCIAL INC	$9.0M	563,375
STATE STREET CORP	$8.4M	529,399
D. E. Shaw & Co., Inc.	$7.7M	486,770
MILLENNIUM MANAGEMENT LLC	$6.4M	401,819

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put FLGT on your watchlist

Track score changes the day Fulgent Genetics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is FLGT a good stock to buy?

13F Pro's AI-powered analysis of Fulgent Genetics, Inc. (FLGT) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for FLGT are available on the FLGT stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own FLGT?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling FLGT. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Fulgent Genetics, Inc.'s investment landscape.